ADVANCED NSCLC
Clinical trials for ADVANCED NSCLC explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NSCLC trials appear
Sign up with your email to follow new studies for ADVANCED NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat lung cancer mutation
Disease control OngoingThis phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…
Matched conditions: ADVANCED NSCLC
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and effectiveness of ningetinib in people with advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. The trial planned to enroll adults aged 18-75 with stage IIIB-IV cancer. However, the stud…
Matched conditions: ADVANCED NSCLC
Phase: PHASE2 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC